The market for Tetanus Toxoid Vaccine reflects the heightening worldwide interests in immunization and general health. Awareness of tetanus, a potentially fatal bacterial infection, has increased necessitating demand for prophylactic measures thereby spurring the growth of the Tetanus Toxoid Vaccine market. It is one of the notable trends that there is a rising up take of vaccination programs in underdeveloped countries with better access to healthcare. Governments and international organizations have made efforts to fight tetanus through immunization campaigns which are responsible for an increase in demand for Tetanus Toxoid Vaccines.
Another important factor shaping market trends is technological advancements and innovations in vaccine development. Continuous research and development (R&D) has led to production of vaccines that are more effective and affordable hence increasing access to these products. This not only broadens the customer base but also makes it possible for a larger population to afford the Tetanus Toxoid Vaccine.
Currently, there is a trend towards multi-dose vaccination approach on this market. Health authorities as well as organizations stress the need for booster doses to maintain lifelong immunity from tetanus infections. Particularly noticeable in high-tetanus regions where regular immunization schedules are revamped with several doses given to both children and adults.
Furthermore, global collaborations and partnerships impact on market dynamics too. Pharmaceutical companies, governments, and international health organizations have often collaborated in addressing issues related to vaccine distribution including accessibility concerns. Gavi – The Vaccine Alliance among other initiatives aims at ensuring that Tetanus Toxoid Vaccines reach rural areas which have no access or limited medical centers where they can be obtained thus achieving greater balance between regional populations.
One other significant trend within this market involves increasing awareness about maternal immunization. The focus on pregnant women who need protection against tetanus as they carry babies along with them when being born into this world is growing stronger every day. This strategy gains momentum due to its potential to lower neonatal and maternal mortalities, thereby stimulating the demand for Tetanus Toxoid Vaccines through antenatal care programs.
Furthermore, regulatory advancements and stringent quality control measures are shaping the market landscape. These agencies have an obligation of ensuring that Tetanus Toxoid Vaccines meet appropriate standards in terms of safety and efficacy. This is important in building consumer trust as well as an environment characterized by competition where manufacturers strive to exceed quality guidelines.
However, vaccine hesitancy and logistical impediments in vaccine distribution still constrain market growth. Therefore, governments, healthcare providers, and vaccine makers must work together to enlighten the public, address concerns about safety of vaccines among others and introduce better ways of distributing these products.“
The Tetanus toxoid vaccine market is projected to reach USD 7,236.2 Million by 2030 at 5.9% CAGR during the forecast period 2024-2030. Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. The spasms may be very severe and even cause bone fractures. Other symptoms include fever, sweating, headache, trouble swallowing, hypertension etc.
About 10% of those infected, die while a large number become incapacitated due to bone fractures. Tetanus toxoid vaccine is an inactive vaccine used to prevent tetanus by developing immunity against the pathogen causing tetanus. The general dosage recommendation is five doses during childhood, with a sixth given during adolescence with additional doses every 10 years.
The tetanus vaccine was initially developed in 1924 and has resulted in a 95% decrease in the rate of tetanus in the US and is on the World Health Organization's List of Essential Medicines. The vaccine also is considered very safe even during pregnancy and for those with HIV.
In February 2022, Ocugen, Inc. (NASDAQ: OCGN) reported that the clinical hold on the Company’s Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) had been lifted in relation to BBV152, its Covid-19 vaccine candidate referred to as COVAXIN™ abroad. The name of this covid-19 vaccine is called COVAXIN™, which is a research vaccine using vero cell production platform for whole-virion inactivated form and has been applied in manufacturing polio vaccines for years. The medicine COVAXIN™ or BBVI52 epitomizes an experimental drug in America.
Bharat Biotech developed COVAXIN™ (BBVI52) using Indian Council of Medical Research-National Institute of Virology (ICMR-NIV). It is manufactured through vero cell culture system and it is an adsorbed killed preparation of vaccine named COVAXIN™.
In August 2022, there was a clinical trial sponsored by IBSS Biomed S.A that assessed immunogenicity as well as safety following a booster immunization with CLODIVAC bivalent vaccine against tetanus & diphtheria (IBSS BIOMED S.A.) & Td-Impfstoff Mérieux – Sanofi Pasteur among healthy adults.
On August 22th 2022 at Kamala Nehru Girls School Auditorium Bhopal, Madhya Pradesh Public Health and Family Welfare Minister set off state-level program on DPT/TD vaccination campaign.
Sanofi Pasteur joined forces with UNICEF in March 2024 to enhance availability of childhood vaccination across Africa.
Pfizer Inc., too, announced mirthful results from Phase III trials of their neoteric respiratory syncytial virus (RSV) vaccine in March 2024.
By February 2024, The Serum Institute of India had made huge financial gains due to a high demand for multiple vaccines including tetanus toxoid vaccine.
The market restraints of the tetanus toxoid vaccine are redness and pain at the site of injection, fever, and fatigue and muscles pains. Severe allergic reactions are the most serious side effects of the Tetanus toxoid vaccine which occur in less than one in 100,000 people. The market for tetanus toxoid vaccine is bipolar with contractual market having a sizable number of share as compared to the private market.
The other market constraints include falling profitability of vaccine manufacturing, huge reduction of tetanus in the developed world which effectively eliminates the need for further vaccination due to herd immunity, side effects associated with vaccines, variability of efficacy of tetanus toxoid vaccine etc.
The low profitability in vaccine manufacturing has reduced incentives for developing vaccines for diseases of the developing world such as tuberculosis and malaria.
Intended Audience
The global tetanus toxoid vaccine market is segmented on the basis of types, forms and end users.
Based on types, the market has been segmented as monovalent tetanus toxoid (TT), diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (Tdap) and others.
Based on the forms, the market has been segmented as quadrivalent, pentavalent, and hexavalent.
Based on the end users, the market has been segmented as biotech and hospitals and clinics, government organizations, research and others.
US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global Tetanus toxoid vaccine. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India.
The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.
Key players profiled in the report are:
The report for Global Tetanus toxoid vaccine market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance.
The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)